There is much research focused on developing new strategies to increase the vitreous residence times of macromolecular drugs to decrease the frequency of intravitreal injections.

The PK-Eye™ is for the evaluation and optimisation of novel ocular formulations and delivery systems for the vitreous. The PK-Eye™ can accelerate the development of longer-lasting therapeutic dosage forms during preclinical development that are needed to treat chronic blinding conditions.